La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Industry: Healthcare

OFF LIST - 792 consecutive market days: OFF LIST as of 04/12/2013 Through 11/14/2016

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Current Quote*
Last: $6.220
Change: 0.000
Book: $Unk
Volume: 100,121

As Of: 08/19 13:01 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol LJPC

  • No BuyIns.Net Alerts Available for LJPC

Graphs for LJPC


3 Month Graph


6 Month Graph


1 Year Graph